Akebia Therapeutics
AKBA
82 hedge funds and large institutions have $146M invested in Akebia Therapeutics in 2015 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 16 reducing their positions, and 11 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 16
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
12% more funds holding
Funds holding: 73 → 82 (+9)
7% more capital invested
Capital invested by funds: $136M → $146M (+$9.98M)
14% less call options, than puts
Call options by funds: $1.23M | Put options by funds: $1.43M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$7.65M |
| 2 |
VAM
Visium Asset Management
New York
|
+$5.1M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$3.49M |
| 4 |
PA
Perceptive Advisors
New York
|
+$2.39M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$2.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.52M |
| 2 |
Renaissance Technologies
New York
|
-$2.48M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$1.97M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.42M |
| 5 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$623K |
AKBA Hedge Fund Activity: Q3 2015 in Review
82 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2015, worth a combined $146M — up 7.4% from $136M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AKBA positions and 11 closed out — a net gain of 9 holders — while 32 added to existing stakes and 16 trimmed.
The largest buyer was Eagle Asset Management, adding an estimated $7.65M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $8.52M sold.
- 82 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2015, up from 73 in Q2 2015.
- Funds reported $146M of Akebia Therapeutics stock for Q3 2015, up 7.4% quarter-over-quarter.
- 20 funds opened new Akebia Therapeutics positions in Q3 2015 and 11 closed out, a net change of +9 holders.
- The largest Akebia Therapeutics buyer in Q3 2015 was Eagle Asset Management, an estimated $7.65M added.
- The largest Akebia Therapeutics seller in Q3 2015 was Balyasny Asset Management, an estimated $8.52M sold.
Based on aggregated 13F filings for Q3 2015.